...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychopharmacology >Betahistine decreases olanzapine-induced weight gain and somnolence in humans
【24h】

Betahistine decreases olanzapine-induced weight gain and somnolence in humans

机译：倍他司汀可降低奥氮平诱导的人的体重增加和嗜睡

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Olanzapine's efficacy in schizophrenia is attributed to antagonism of dopamine and serotonin receptors. Olanzapine is also a potent histamine-H1 antagonist that results in weight gain and somnolence. Betahistine is a centrally acting histamine-H1 agonist, and therefore may reduce olanzapine's effect on histamine receptors in the brain. Olanzapine's high affinity for the histamine-H1 receptor warrants the use of high doses of betahistine. Forty-eight healthy women were recruited and randomized to receive either betahistine 144 mg/day or matching placebo for 4 weeks. Due to the high dose of betahistine, olanzapine was started only on the second week and titrated up to 10 mg/day, and co-administration continued for an additional 2 weeks. Only nominal differences in adverse events were noted between the treatment groups. Betahistine caused a 37% reduction in mean weight gain (1.24 kg in the betahistine arm vs. 1.93 kg in the placebo arm; p=.049) and 60% reduction in the mean increase in daytime Epworth sleepiness scores (1.82 units in the betahistine group vs. 3.57 units in the placebo group; p=.042). The present study suggests that betahistine-olanzapine co-administration, in healthy female subjects, yields an acceptable safety profile with mitigation of weight gain and somnolence. This should be further tested in a patient cohort.
机译：奥氮平在精神分裂症中的功效归因于多巴胺和5-羟色胺受体的拮抗作用。奥氮平还是有效的组胺-H1拮抗剂，可导致体重增加和嗜睡。 Betahistine是一种中枢作用的组胺H1激动剂，因此可能会降低奥氮平对大脑中组胺受体的作用。奥氮平对组胺-H1受体的高度亲和力可确保使用大剂量的倍他司汀。招募了48名健康女性，并随机分组接受甜菜碱144 mg /天或匹配的安慰剂治疗4周。由于倍他司汀的高剂量，奥氮平仅在第二周才开始使用，滴定至每天10毫克，然后继续共同给药2周。在治疗组之间仅注意到不良事件的名义差异。 Betahistine导致平均体重增加减少37％（betahistine组为1.24公斤，安慰剂组为1.93 kg; p = .049），日间Epworth嗜睡分数平均增加量减少60％（betahistine为1.82单位）组与安慰剂组的3.57个单位; p = .042）。本研究表明，在健康的女性受试者中，倍他司汀-奥氮平共同给药可减轻体重增加和嗜睡，产生可接受的安全性。这应该在患者队列中进行进一步测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号